EGFR inhibitors (e.g., erlotinib, gefitinib) inhibit ATP binding to the tyrosine kinase domain of EGFR, preventing receptor autophosphorylation, thereby inhibiting downstream signaling through the RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways in cancer cells [96]. This evidence concerns the gene MAP2K7 and cancer.